56 A Phase 2 Exploratory Study of Intravenous Cetirizine Versus Intravenous Diphenhydramine in the Prevention of Hypersensitivity Infusion Reactions in Patients With Breast Cancer and Other Malignancies

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1
Pages: 25-26

Jarrod P. Holmes, MD, FACP1; Constantin A. Dasanu, MD, PhD2; Julio Peguero, MD3; Ahmed Ayad, MD3; R. Campbell Garland, DO4; Anne O’Shea, MD5; G. Travis Clifton, MD5; George Peoples, MD, FACS6; Stacia Young, PharmD, BCOP, MBA7; Teresa Yang, BSN, MBA; Janine North, BS; Nancy Joseph-Ridge, MD7

1St. Joseph Health Medical Group Sonoma, Santa Rosa, CA

2Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA

3Oncology Consultants, Houston, TX

4Baylor Scott & White Medical Center – Temple, Temple, TX

5Department of Surgery, Brooke Army Medical Center, Fort Sam Houston, TX

6Cancer Vaccine Development Program, San Antonio, TX

7TerSera Therapeutics, Carmel, CA

Background

Antihistamine pretreatment for drug-induced hypersensitivity infusion reactions (IRs) is recommended with certain breast cancer treatments, including paclitaxel.1-5 The only second-generation intravenous (IV) antihistamine currently available is IV cetirizine.6 Intravenous cetirizine was shown to treat acute urticaria comparably to IV diphenhydramine, with fewer adverse effects (AEs), and may be effective for pretreatment of IRs.7

Materials and Methods

This randomized, double-blind, phase 2 study evaluated pretreatment with single-dose IV cetirizine 10 mg versus IV diphenhydramine 50 mg in 34 patients receiving paclitaxel, rituximab (Rituxan), its biosimilar, or obinutuzumab (Gazyva) (first cycle, retreatment after 6 months or in patients with persistent IRs). The primary objective of the study was to compare the incidence of IRs after pretreatment with the 2 medications. The key secondary end point was sedation score due to IV antihistamines. The study also evaluated the need for rescue medication and the time to readiness for discharge. During and following infusion, IR symptoms, such as flushing, urticaria, and dyspnea, were assessed. Sedation was measured by health care providers on a scale of 0 to 4 (where 0 = no sedation and 4 = extreme sedation). Due to the exploratory nature of the study, no formal statistical analyses were planned.

Results

Adult patients primarily with hematologic and solid tumor malignancies, including breast cancer, were enrolled between March 26, 2020 and November 23, 2020. The median age was 65 years for the IV cetirizine group and 67 years for the IV diphenhydramine group. The number of patients who experienced an IR was 2 out of 17 (11.8%) with IV cetirizine versus 4 out of 17 (23.5%) with IV diphenhydramine. Mean sedation scores (standard deviation [SD]) in the IV cetirizine group were 0.47 (0.80), 0.63 (0.89), and 0.18 (0.39), compared with 1.00 (1.46), 0.76 (1.13), and 0.35 (1.00) in the IV diphenhydramine group at 1 hour, 2 hours, and discharge, respectively. Results were similar with patient-rated sedation scores. Mean time for readiness for discharge was 25 minutes shorter with IV cetirizine versus IV diphenhydramine. There were fewer treatment-related AEs with IV cetirizine (1 event) than with IV diphenhydramine (3 events).

Conclusion

This was the first prospective, randomized, controlled trial evaluating IV antihistamine pretreatment for the prevention of IRs. The results of this study demonstrated that IV cetirizine was as effective as IV diphenhydramine for the prevention of IRs due to paclitaxel or an anti-CD20 agent, with less sedation and fewer treatment-related AEs.

References:

1. Gobel BH. Chemotherapy-induced hypersensitivity reactions. Oncol Nurs Forum. 2005;32(5):1027-1035. doi:10.1188/05.onf.1027-1035

2. Joerger M. Prevention and handling of acute allergic and infusion reactions in oncology. Ann Oncol. 2012;23(suppl 10):x313–x319. doi:10.1093/annonc/mds314

3. Paclitaxel. Package insert. Hospira Inc; 2018.

4. NCCN. Clinical Practice Guidelines in Oncology. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer, version 1.2021. Accessed March 18, 2021. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf

5. Roselló S, Blasco I, García Fabregat L, Cervantes A, Jordan K; ESMO Guidelines Committee. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2017;28(suppl_4):iv100-iv118. doi:10.1093/annonc/mdx216

6. QUZYTTIR. Package insert. TerSera Therapeutics LLC; 2019.

7. Abella BS, Berger WE, Blaiss MS, et al. Intravenous cetirizine versus intravenous diphenhydramine for the treatment of acute urticaria: a phase III randomized controlled noninferiority trial. Ann Emerg Med. 2020;76(4):489-500. doi:10.1016/j.annemergmed.2020.05.025

Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients